JP5785360B2 - 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 - Google Patents
炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 Download PDFInfo
- Publication number
- JP5785360B2 JP5785360B2 JP2009521271A JP2009521271A JP5785360B2 JP 5785360 B2 JP5785360 B2 JP 5785360B2 JP 2009521271 A JP2009521271 A JP 2009521271A JP 2009521271 A JP2009521271 A JP 2009521271A JP 5785360 B2 JP5785360 B2 JP 5785360B2
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formula
- nasal
- compound
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](C[C@@]([C@@](C1C[C@@]2F)(C(C)(C=C3)C2=CC3=O)F)O)(C1C=C1C)[C@]1(C(SCF)=O)OC(c1c(*)nc[s]1)=O Chemical compound C[C@](C[C@@]([C@@](C1C[C@@]2F)(C(C)(C=C3)C2=CC3=O)F)O)(C1C=C1C)[C@]1(C(SCF)=O)OC(c1c(*)nc[s]1)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
(i)式(I)で示される化合物またはその塩もしくは溶媒和物の水溶液と、
(ii)式(II)で示される化合物、式(III)で示される化合物、式(IV)で示される化合物、および式(V)で示される化合物よりなる群から選択されるコルチコステロイドの水性懸濁物と、
(iii)1種以上の懸濁化剤と、
(iv)1種以上の保存剤と、
(v)1種以上の湿潤剤と、
(vi)緩衝剤と、
(vii)1種以上の等張性調整剤と、場合により
(viii)1種以上の味マスキング剤と、
を含む医薬製剤を提供する。
有機塩および無機塩、たとえば、限定されるものではないが、リン酸ナトリウムまたはリン酸カルシウム、マグネシウムステアレート、ならびにそれらの組合せおよび誘導体;
ポリマー、たとえば、天然生分解性タンパク質ポリマー、たとえば、限定されるものではないが、ゼラチン、ならびにそれらの組合せおよび誘導体;
天然生分解性ポリサッカリドポリマー、たとえば、限定されるものではないが、キチンおよびデンプン、架橋型デンプン、ならびにそれらの組合せおよび誘導体;
半合成生分解性ポリマー、たとえば、限定されるものではないが、キトサンの誘導体;
合成生分解性ポリマー、たとえば、限定されるものではないが、ポリエチレングリコール(PEG)、ポリ乳酸(PLA)、合成ポリマー、たとえば、限定されるものではないが、ポリビニルアルコール、ならびにそれらの組合せおよび誘導体;
アミノ酸、たとえば、限定されるものではないが、非極性アミノ酸、具体的には、ロイシン、ならびにそれらの組合せおよび誘導体;
リン脂質、たとえば、レシチン、ならびにそれらの組合せおよび誘導体;
湿潤剤/界面活性剤/乳化剤、たとえば、限定されるものではないが、アカシアガム、コレステロール、脂肪酸、さらにはそれらの組合せおよび誘導体;
ポロキサマー/プルロニック、たとえば、限定されるものではないが、ポロキサマー188、プルロニック(登録商標)F-108、ならびにそれらの組合せおよび誘導体;
イオン交換樹脂、たとえば、限定されるものではないが、アンバーライトIR120、ならびにそれらの組合せおよび誘導体;
さらには記載の賦形剤の組合せ。
鼻腔内送達用の製剤は、以下の成分を用いて調製可能である。
Claims (13)
- 式(II)で示される化合物が6α,9α-ジフルオロ-17α-[(2-フラニルカルボニル)オキシ]-11β-ヒドロキシ-16α-メチル-3-オキソ-アンドロスタ-1,4-ジエン-17β-カルボチオ酸S-フルオロメチルエステルである、請求項1に記載の経鼻製剤。
- 式(I)で示される化合物がラセミ形または単一のエナンチオマーのいずれかのアゼラスチンである、請求項1または2に記載の経鼻製剤。
- 前記アゼラスチンが塩酸塩として存在する、請求項3に記載の経鼻製剤。
- 1種以上の懸濁化剤をさらに含む、請求項1〜4のいずれか1項に記載の経鼻製剤。
- 1種以上の保存剤を含む、請求項1〜5のいずれか1項に記載の経鼻製剤。
- 1種以上の湿潤剤を含む、請求項1〜6のいずれか1項に記載の経鼻製剤。
- 1種以上の等張性調整剤を含む、請求項1〜7のいずれか1項に記載の経鼻製剤。
- 緩衝剤を含む、請求項1〜8のいずれか1項に記載の経鼻製剤。
- 1種以上の味マスキング剤を含む、請求項1〜9のいずれか1項に記載の経鼻製剤。
- (i)式(I)で示される化合物またはその塩の水溶液と、
(ii)式(II)で示される化合物であるコルチコステロイドの水性懸濁物と、
(iii)1種以上の懸濁化剤と、
(iv)1種以上の保存剤と、
(v)1種以上の湿潤剤と、
(vi)緩衝剤と、
(vii)1種以上の等張性調整剤と、場合により
(viii)1種以上の味マスキング剤と、
を含む、請求項1〜10のいずれか1項に記載の経鼻製剤。 - 人間医学または獣医学において炎症病態および/またはアレルギー病態を有する患者の治療で使用するための、請求項1〜11のいずれか1項に記載の経鼻製剤。
- 炎症病態および/またはアレルギー病態を有する患者を治療するための、請求項1〜11のいずれか1項に記載の経鼻製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0615108.8 | 2006-07-28 | ||
GBGB0615108.8A GB0615108D0 (en) | 2006-07-28 | 2006-07-28 | Novel formulations |
PCT/EP2007/057695 WO2008012338A2 (en) | 2006-07-28 | 2007-07-26 | Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009544665A JP2009544665A (ja) | 2009-12-17 |
JP2009544665A5 JP2009544665A5 (ja) | 2010-08-26 |
JP5785360B2 true JP5785360B2 (ja) | 2015-09-30 |
Family
ID=37006420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009521271A Active JP5785360B2 (ja) | 2006-07-28 | 2007-07-26 | 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090286762A1 (ja) |
EP (1) | EP2046338A2 (ja) |
JP (1) | JP5785360B2 (ja) |
GB (1) | GB0615108D0 (ja) |
WO (1) | WO2008012338A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
WO2012094283A2 (en) * | 2011-01-04 | 2012-07-12 | Ista Pharmaceuticals, Inc. | Bepotastine compositions |
JP6267685B2 (ja) | 2012-04-13 | 2018-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 集合粒子 |
JP6294893B2 (ja) * | 2012-12-17 | 2018-03-14 | グラクソ グループ リミテッドGlaxo Group Limited | 炎症性及び/又はアレルギー性の状態を治療するためのレボカバスチンとフルチカゾンフランカルボン酸エステルとの併用 |
GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
JP6545148B2 (ja) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ,エルエルシー | ピリダジノン化合物及び嚢胞性線維症の治療のための方法 |
US9937189B2 (en) | 2013-09-13 | 2018-04-10 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
PT3043773T (pt) * | 2013-09-13 | 2021-10-04 | Glenmark Specialty Sa | Composição farmacêutica de dose fixa estável composta por mometasona e olopatadina para administração nasal |
CN110248643B (zh) | 2017-02-13 | 2023-11-24 | 拜耳动物保健有限责任公司 | 含普拉沙星的液体组合物 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2837464A (en) * | 1955-01-11 | 1958-06-03 | Schering Corp | Process for production of dienes by corynebacteria |
US3067197A (en) * | 1961-04-26 | 1962-12-04 | Pfizer & Co C | 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives |
GB1047518A (en) * | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
GB1159490A (en) * | 1966-02-09 | 1969-07-23 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
GB1227992A (ja) * | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
IT1034011B (it) * | 1969-06-26 | 1979-09-10 | Vister Vismara Terapeutici S P | Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato |
US3828080A (en) * | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
US3989686A (en) * | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
GB1440063A (en) * | 1972-08-11 | 1976-06-23 | Glaxo Lab Ltd | 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids |
GB1517278A (en) * | 1974-08-30 | 1978-07-12 | Glaxo Lab Ltd | Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
YU54476A (en) * | 1975-03-31 | 1982-05-31 | Taisho Pharmaceutical Co Ltd | Process for obtaining 17-ester 21-halo-pregnane |
CH628355A5 (de) * | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
US4221787A (en) * | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
US4198403A (en) * | 1978-04-05 | 1980-04-15 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
US4263289A (en) * | 1978-04-05 | 1981-04-21 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4188385A (en) * | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
US4187301A (en) * | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
US4261984A (en) * | 1978-04-05 | 1981-04-14 | Syntex (U.S.A.) Inc. | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes |
DE2817988A1 (de) * | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
US4310466A (en) * | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
US4335121A (en) * | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
US4710495A (en) * | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
CY1359A (en) * | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4607028A (en) * | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
US4861765A (en) * | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5202316A (en) * | 1989-03-22 | 1993-04-13 | Roussel Uclaf | N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines |
FR2644788B1 (fr) * | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
JPH07116215B2 (ja) * | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
DE4025342A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US6127353A (en) * | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
DE4328819A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE4333920A1 (de) * | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
GB9419536D0 (en) * | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
US5707984A (en) * | 1995-12-08 | 1998-01-13 | G. D. Searle & Co. | Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs |
ES2150150T3 (es) * | 1995-12-29 | 2000-11-16 | Glaxo Group Ltd | Derivados de lactona de derivados de 17-beta-carboxi, carbonato y amida androstano. |
US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
FR2779841B1 (fr) * | 1998-06-15 | 2006-08-04 | Peugeot | Procede et dispositif de commande d'un actionneur electrique d'activation d'un systeme fonctionnel |
US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020081266A1 (en) * | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
AR032361A1 (es) * | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
US6858593B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777400B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
CA2438799C (en) * | 2000-12-22 | 2009-09-01 | Ssp Co., Ltd. | Preventative of therapeutic agent for inflammatory respiratory tract disease |
UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
JP3691459B2 (ja) * | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
PT2522365T (pt) * | 2004-11-24 | 2017-02-08 | Meda Pharmaceuticals Inc | Composições que compreendem azelastina e seus métodos de utilização |
-
2006
- 2006-07-28 GB GBGB0615108.8A patent/GB0615108D0/en not_active Ceased
-
2007
- 2007-07-26 JP JP2009521271A patent/JP5785360B2/ja active Active
- 2007-07-26 US US12/374,523 patent/US20090286762A1/en not_active Abandoned
- 2007-07-26 WO PCT/EP2007/057695 patent/WO2008012338A2/en active Application Filing
- 2007-07-26 EP EP07787921A patent/EP2046338A2/en not_active Withdrawn
-
2011
- 2011-08-08 US US13/204,978 patent/US20120065177A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2009544665A (ja) | 2009-12-17 |
WO2008012338A2 (en) | 2008-01-31 |
EP2046338A2 (en) | 2009-04-15 |
GB0615108D0 (en) | 2006-09-06 |
WO2008012338A3 (en) | 2009-01-08 |
US20090286762A1 (en) | 2009-11-19 |
US20120065177A1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5785360B2 (ja) | 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 | |
Pires et al. | Intranasal drug delivery: how, why and what for? | |
US10064817B2 (en) | Compositions comprising azelastine and methods of use thereof | |
US8758816B2 (en) | Compositions comprising azelastine and methods of use thereof | |
US9919050B2 (en) | Compositions comprising azelastine | |
AU2012204557B2 (en) | Bepotastine compositions | |
WO2007061454A1 (en) | Compositions comprising azelastine and methods of use thereof | |
US20160287612A1 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
US20180000843A1 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
JP6294893B2 (ja) | 炎症性及び/又はアレルギー性の状態を治療するためのレボカバスチンとフルチカゾンフランカルボン酸エステルとの併用 | |
US20040044035A1 (en) | Novel aqueous anti-inflammatory pharmaceutical formulation | |
US20040034062A1 (en) | Novel aqueous anti-inflammatory pharmaceutical formulation | |
RU2687551C2 (ru) | Стабильная фармацевтическая композиция с фиксированной дозой, содержащая мометазон и олопатадин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100707 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100707 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121016 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150403 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150724 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5785360 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |